title: [Treatment of Behçet's disease with adalimumab].
authors.forename: José Luis
authors.initials: JL
authors.lastname: Callejas-Rubio
authors.forename: Daniel
authors.initials: D
authors.lastname: Sánchez-Cano
authors.forename: Raquel
authors.initials: R
authors.lastname: Ríos-Férnandez
authors.forename: Norberto
authors.initials: N
authors.lastname: Ortego-Centeno
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001528:Behcet Syndrome / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D000068879:Adalimumab; D008727:Methotrexate